Effect of the Growth Hormone MAXOMAT ® on the Growth of Small Children and Adolescents (<-2 SD) Due to NOONAN's Syndrome

NCT00452725 Phase 3 COMPLETED

1. Clinical Objective : To improve the growth of these children 2. Genetic objective : A study of the genetics of the syndrome

Details

Lead sponsor	Sanofi
Phase	Phase 3
Status	COMPLETED
Enrolment	36
Start date	1997-10
Completion	2010-07

Conditions

• Noonan Syndrome

Interventions

• MAXOMAT ®, biosynthetic growth hormone

Primary outcomes

• Evaluation of height : gain in height and rate of growth — at each visit (every 3 months) or every 6 months

Countries

France